{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:32:18Z","timestamp":1785551538267,"version":"3.56.0"},"reference-count":16,"publisher":"FapUNIFESP (SciELO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"abstract":"<jats:p>Summary Hodgkin\u2019s lymphoma (HL) is a tumor comprising non-malignant and malignant B-cells. Classical HL expresses CD15+ and CD30+ antigens, and 20 to 40% of patients are CD20+. This antigen is a ligand free protein present in B lymphocyte cells and its function is not well known. Some studies suggest that expression of CD20 may play a major role in Hodgkin\u2019s disease pathophysiology and may affect the patients\u2019 treatment prognosis, as well as relapse and refractory response. In the past few years, development of monoclonal anti-CD20 antibodies changed drastically the treatment for non-Hodgkin lymphomas in which CD20 is expressed. HL treatment is essentially composed of radiotherapy and chemotherapy; however, monoclonal anti-CD20 antibodies applicability is not well delimitated due to lack of information about clinical outcomes with anti-CD20 monotherapy or combined drug therapy using a classic regimen, as well as about CD20 pathophysiology mechanisms in B-cells tumors. The objective of our review is to discuss CD20 function in Hodgkin\u2019s lymphoma development, its influence on disease evolution and outcomes, as well as its effects on therapeutics and patients\u2019 prognostic.<\/jats:p>","DOI":"10.1590\/1806-9282.63.09.810","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T14:16:13Z","timestamp":1513347373000},"page":"810-813","source":"Crossref","is-referenced-by-count":17,"title":["CD20 role in pathophysiology of Hodgkin\u2019s disease"],"prefix":"10.1590","volume":"63","author":[{"given":"Marcelo Ant\u00f4nio Oliveira","family":"Santos","sequence":"first","affiliation":[{"name":"Universidade Federal de Pernambuco, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus de Moraes","family":"Lima","sequence":"additional","affiliation":[{"name":"Centro Universit\u00e1rio Maur\u00edcio de Nassau, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2017]]},"reference":[{"issue":"51","key":"ref1","doi-asserted-by":"crossref","first-page":"20729","DOI":"10.1073\/pnas.1312509110","article-title":"Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells","volume":"110","author":"Rengstl B","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","article-title":"Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome","volume":"31","author":"Greaves P","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/annonc\/13.S1.11","article-title":"Biology of Hodgkin's lymphoma","volume":"13","author":"K\u00fcppers R","year":"2002","journal-title":"Ann Oncol"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"K\u00fcppers R","year":"2012","journal-title":"J Clin Invest"},{"issue":"9844","key":"ref5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(12)60035-X","article-title":"Hodgkin's lymphoma in adults","volume":"380","author":"Townsend W","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial","volume":"101","author":"Ekstrand BC","year":"2003","journal-title":"Blood"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.critrevonc.2012.07.002","article-title":"Hodgkin lymphoma","volume":"85","author":"Gobbi PG","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMe0912481","article-title":"Toward a personalized treatment for Hodgkin's disease","volume":"362","author":"DeVitta Jr VT","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1073\/pnas.85.1.208","article-title":"Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes","volume":"85","author":"Tedder TF","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","article-title":"Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains","volume":"7","author":"Einfeld DA","year":"1988","journal-title":"EMBO J"},{"issue":"5","key":"ref11","first-page":"1278","article-title":"CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presentinf features and clinical outcome","volume":"20","author":"Rassidakis GZ","year":"2002","journal-title":"J Clin Oncol"},{"issue":"21","key":"ref12","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1056\/NEJMct1114348","article-title":"Anti-CD20 antibody therapy for B-cell lymphomas","volume":"366","author":"Maloney DG","year":"2012","journal-title":"N Engl J Med"},{"issue":"18","key":"ref13","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2012-03-413146","article-title":"Off-targeting oft-targeted CD20 in cHL","volume":"119","author":"Gordon LI","year":"2012","journal-title":"Blood"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11899-010-0052-z","article-title":"Does rituximab have a place in treating classic Hodgkin lymphoma","volume":"5","author":"Oki Y","year":"2010","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"ref15","first-page":"1381","article-title":"Prognostic significance of CD20 expression in classical Hodgkin lymphoma","volume":"9","author":"Tzankov A","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"ref16","first-page":"1101","article-title":"Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma","volume":"24","author":"Horvat M","year":"2010","journal-title":"Oncol Rep"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v63n9\/0104-4230-ramb-63-09-0810.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T23:15:29Z","timestamp":1570490129000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302017000900810&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017]]}},"alternative-id":["S0104-42302017000900810"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.63.09.810","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"value":"1806-9282","type":"electronic"},{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}